The march toward malaria vaccines

Vaccine
S L HoffmanPatrick Duffy

Abstract

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the existing armamentarium of anti-malaria tools. However, malaria is caused by parasites, and parasites are much more complex in terms of their biology than the viruses and bacteria for which we have vaccines, passing through multiple stages of development in the human host, each stage expressing hundreds of unique antigens. This complexity makes it more difficult to develop a vaccine for parasites than for viruses and bacteria, since an immune response targeting one stage may not offer protection against a later stage, because different antigens are the targets of protective immunity at different stages. Furthermore, depending on the life cycle stage and whether the parasite is extra- or intra-cellular, antibody and/or cellular immune responses provide protection. It is thus not surprising that there is no vaccine on the market for prevention of malaria, or any human parasitic infection. In fact, no vaccine for any disease with this breadth of targets and immune responses exists. In this limited review, we focus on four approaches to malaria vaccines, (1)...Continue Reading

References

Jan 1, 1974·Transactions of the Royal Society of Tropical Medicine and Hygiene·K H RieckmannK W Sell
Nov 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·J RenerL H Miller
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·M SedegahS L Hoffman
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·M SedegahS L Hoffman
Feb 15, 2001·The Journal of Infectious Diseases·K E KesterUNKNOWN RTS,S Malaria Vaccine Evaluation Group
Apr 4, 2002·The Journal of Infectious Diseases·Stephen L HoffmanThomas L Richie
Nov 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yimin WuLouis H Miller
Aug 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Rhoel R DinglasanMarcelo Jacobs-Lorena
Oct 13, 2007·Expert Review of Vaccines·Nathalie GarçonMarcelle Van Mechelen
Jul 7, 2009·Annual Review of Microbiology·Ahmed S I AlyStefan H I Kappe
Jul 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Kelley M VanBuskirkStefan H I Kappe
Jul 31, 2009·The New England Journal of Medicine·Meta RoestenbergRobert Sauerwein
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Nhat-Long L PhamJohn T Harty
Feb 12, 2011·PLoS Medicine·UNKNOWN malERA Consultative Group on Vaccines
Oct 20, 2011·The New England Journal of Medicine·UNKNOWN RTS,S Clinical Trials PartnershipPreeti Vansadia
Dec 8, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dung T LeDaniel A Laheru

❮ Previous
Next ❯

Citations

Nov 13, 2015·Expert Review of Vaccines·Eizo TakashimaTakafumi Tsuboi
Sep 1, 2015·Vaccine·Andrew W ArtensteinGlen Nowak
Nov 23, 2015·American Journal of Preventive Medicine·Andrew W ArtensteinGlen J Nowak
May 10, 2016·Nature Medicine·Andrew S IshizukaRobert A Seder
Mar 25, 2016·FEBS Letters·Friedrich Frischknecht, Oliver T Fackler
Nov 12, 2016·International Journal for Parasitology·J Kevin Baird
Oct 23, 2016·Vaccine·Anthony L CunninghamPeter Stern
Oct 11, 2016·The Journal of Parasitology·Emma R ColdJosé A Fernández Robledo
Mar 10, 2018·NPJ Vaccines·Camila Henriques CoelhoPatrick E Duffy
Dec 20, 2017·Cold Spring Harbor Perspectives in Biology·Lalit K BeuraDavid Masopust
Feb 10, 2017·Clinical and Vaccine Immunology : CVI·Eduardo AlvesArturo Reyes-Sandoval
Dec 18, 2015·Clinical and Vaccine Immunology : CVI·Matthew B Laurens
Nov 30, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Said A JongoStephen L Hoffman
Aug 30, 2019·Nature Reviews. Immunology·Jean-Philippe Julien, Hedda Wardemann
Feb 23, 2017·Proceedings of the National Academy of Sciences of the United States of America·Kirsten E LykeRobert A Seder
May 4, 2017·Parasites & Vectors·Corine G DemangaJohn P Dalton
Jul 1, 2017·Frontiers in Cellular and Infection Microbiology·Jonnel A Jaurigue, Peter H Seeberger
Aug 4, 2018·Frontiers in Cellular and Infection Microbiology·Ahmad Syibli OthmanShahid M Khan
Jun 23, 2020·NPJ Vaccines·Patrick E Duffy, J Patrick Gorres
Jun 21, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ryan ChoiKayode K Ojo
Jan 9, 2019·Frontiers in Immunology·Leslie S ItsaraAnil K Ghosh
Oct 27, 2018·European Journal of Medicinal Chemistry·Anne BouchutJamal Khalife
Feb 6, 2021·Vaccines·José Manuel LozanoJuan Edilberto Rincón
Feb 14, 2021·NPJ Vaccines·Patrick E Duffy, J Patrick Gorres

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.